Literature DB >> 21200394

Bone metastasis: mechanisms and therapeutic opportunities.

Larry J Suva1, Charity Washam, Richard W Nicholas, Robert J Griffin.   

Abstract

The skeleton is one of the most common sites for metastatic cancer, and tumors arising from the breast or prostate possess an increased propensity to spread to this site. The growth of disseminated tumor cells in the skeleton requires tumor cells to inhabit the bone marrow, from which they stimulate local bone cell activity. Crosstalk between tumor cells and resident bone and bone marrow cells disrupts normal bone homeostasis, which leads to tumor growth in bone. The metastatic tumor cells have the ability to elicit responses that stimulate bone resorption, bone formation or both. The net result of these activities is profound skeletal destruction that can have dire consequences for patients. The molecular mechanisms that underlie these painful and often incurable consequences of tumor metastasis to bone are beginning to be recognized, and they represent promising new molecular targets for therapy.
© 2011 Macmillan Publishers Limited. All rights reserved

Entities:  

Mesh:

Year:  2011        PMID: 21200394      PMCID: PMC3134309          DOI: 10.1038/nrendo.2010.227

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


  124 in total

Review 1.  Metastasis to bone: causes, consequences and therapeutic opportunities.

Authors:  Gregory R Mundy
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

2.  Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.

Authors:  Manali S Bendre; Aaron G Margulies; Brandon Walser; Nisreen S Akel; Sudeepa Bhattacharrya; Robert A Skinner; Frances Swain; Vishnu Ramani; Khalid S Mohammad; Lisa L Wessner; Alfredo Martinez; Theresa A Guise; John M Chirgwin; Dana Gaddy; Larry J Suva
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

3.  Systemic administration of acidic fibroblast growth factor (FGF-1) prevents bone loss and increases new bone formation in ovariectomized rats.

Authors:  C R Dunstan; R Boyce; B F Boyce; I R Garrett; E Izbicka; W H Burgess; G R Mundy
Journal:  J Bone Miner Res       Date:  1999-06       Impact factor: 6.741

4.  Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease.

Authors:  Sonia Vallet; Siddhartha Mukherjee; Nileshwari Vaghela; Teru Hideshima; Mariateresa Fulciniti; Samantha Pozzi; Loredana Santo; Diana Cirstea; Kishan Patel; Aliyah R Sohani; Alex Guimaraes; Wanling Xie; Dharminder Chauhan; Jesse A Schoonmaker; Eyal Attar; Michael Churchill; Edie Weller; Nikhil Munshi; Jasbir S Seehra; Ralph Weissleder; Kenneth C Anderson; David T Scadden; Noopur Raje
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-01       Impact factor: 11.205

Review 5.  The role of Wnts in bone metastases.

Authors:  Christopher L Hall; Evan T Keller
Journal:  Cancer Metastasis Rev       Date:  2006-12       Impact factor: 9.264

6.  Metastasizing potentials of mouse mammary tumors and their metastases.

Authors:  J Vaage
Journal:  Int J Cancer       Date:  1988-06-15       Impact factor: 7.396

Review 7.  Skeletal complications of malignancy.

Authors:  R E Coleman
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

8.  Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition.

Authors:  Victor D Acevedo; Rama D Gangula; Kevin W Freeman; Rile Li; Youngyou Zhang; Fen Wang; Gustavo E Ayala; Leif E Peterson; Michael Ittmann; David M Spencer
Journal:  Cancer Cell       Date:  2007-12       Impact factor: 31.743

Review 9.  Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins.

Authors:  Jennifer M Bailey; Pankaj K Singh; Michael A Hollingsworth
Journal:  J Cell Biochem       Date:  2007-11-01       Impact factor: 4.429

Review 10.  Role of endothelin-1 in osteoblastic bone metastases.

Authors:  Theresa A Guise; Juan Juan Yin; Khalid S Mohammad
Journal:  Cancer       Date:  2003-02-01       Impact factor: 6.860

View more
  136 in total

Review 1.  MRI-guided focused ultrasound surgery in musculoskeletal diseases: the hot topics.

Authors:  Alberto Bazzocchi; Alessandro Napoli; Beatrice Sacconi; Giuseppe Battista; Giuseppe Guglielmi; Carlo Catalano; Ugo Albisinni
Journal:  Br J Radiol       Date:  2015-11-26       Impact factor: 3.039

2.  Role of Runx2 in IGF-1Rβ/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis.

Authors:  M Tandon; Z Chen; A H Othman; J Pratap
Journal:  Oncogene       Date:  2016-01-25       Impact factor: 9.867

3.  Galectin-3 Cleavage Alters Bone Remodeling: Different Outcomes in Breast and Prostate Cancer Skeletal Metastasis.

Authors:  Kosei Nakajima; Dhong Hyo Kho; Takashi Yanagawa; Yosuke Harazono; Victor Hogan; Wei Chen; Rouba Ali-Fehmi; Rohit Mehra; Avraham Raz
Journal:  Cancer Res       Date:  2016-02-02       Impact factor: 12.701

Review 4.  Bone metastasis and the metastatic niche.

Authors:  Guangwen Ren; Mark Esposito; Yibin Kang
Journal:  J Mol Med (Berl)       Date:  2015-08-15       Impact factor: 4.599

5.  Metastatic dissemination patterns of different primary tumors to the spine and other bones.

Authors:  Julia S Onken; Lucius S Fekonja; Romy Wehowsky; Vanessa Hubertus; Peter Vajkoczy
Journal:  Clin Exp Metastasis       Date:  2019-08-16       Impact factor: 5.150

6.  Early osteosclerotic changes predict chemotherapy response in non-small-cell lung cancer patients with bone metastases.

Authors:  Dailin Rong; Yize Mao; Qiuxia Yang; Shuhang Xu; Qianqian Zhao; Rong Zhang
Journal:  Eur Radiol       Date:  2018-04-12       Impact factor: 5.315

7.  Update on bone-modifying agents in metastatic breast cancer.

Authors:  Larry J Suva; Brooke E Brander; Issam Makhoul
Journal:  Nat Rev Endocrinol       Date:  2011-05-24       Impact factor: 43.330

8.  Tumor dormancy in bone.

Authors:  Vera Mayhew; Tolu Omokehinde; Rachelle W Johnson
Journal:  Cancer Rep (Hoboken)       Date:  2019-01-29

9.  Development and characterization of murine models of medulloblastoma extraneural growth in bone.

Authors:  Jessica M Grunda; Dezhi Wang; Gregory A Clines
Journal:  Clin Exp Metastasis       Date:  2013-03-15       Impact factor: 5.150

10.  Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor.

Authors:  Chao Zhang; Prabha N Ibrahim; Jiazhong Zhang; Elizabeth A Burton; Gaston Habets; Ying Zhang; Ben Powell; Brian L West; Bernice Matusow; Garson Tsang; Rafe Shellooe; Heidi Carias; Hoa Nguyen; Adhirai Marimuthu; Kam Y J Zhang; Angela Oh; Ryan Bremer; Clarence R Hurt; Dean R Artis; Guoxian Wu; Marika Nespi; Wayne Spevak; Paul Lin; Keith Nolop; Peter Hirth; Greg H Tesch; Gideon Bollag
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.